Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences pays a quarterly dividend of $0.82 per share, equating to an annualized dividend of $3.28 and a dividend yield of approximately 2.5%.
• The company has raised its dividend every year since initiating payments in 2015, marking an 11-year dividend growth streak.
• With a payout ratio of roughly 43% to 49% and a free cash flow payout ratio near 40%, the dividend appears well-covered by both earnings and cash flow.
• Gilead's dividend yield sits comfortably above the healthcare sector average of approximately 1.66%, making it one of the more attractive income plays in biopharma.
• The company generated more than $8 billion in free cash flow, providing ample room for continued dividend increases and share repurchases.

Dividend Overview

GILD has established itself as a consistent dividend payer within the biopharmaceutical industry. The company distributes dividends on a quarterly schedule, with its most recent quarterly payment set at $0.82 per share. Based on the annualized payout of $3.28, the stock offers a dividend yield of approximately 2.5%, which is notably above the broader healthcare sector average of about 1.66%. While Gilead does not fall into the high-yield category, it occupies a solid middle ground — offering a yield that is meaningfully higher than many of its large-cap peers while maintaining a disciplined payout structure. The company is best characterized as a dividend growth stock rather than a high-yield play, with management demonstrating a consistent commitment to returning capital to shareholders through steadily rising dividends since the program's inception.

Dividend History and Growth

Gilead Sciences initiated its dividend program in 2015 with a quarterly payment of $0.43 per share and has increased the payout every year since. The annual per-share dividend has grown from $1.72 in 2015 to $3.28 on a current run-rate basis — an impressive cumulative increase. Over the past five years, the dividend has compounded at an average annual rate of approximately 3% to 4%, while the 10-year compound annual growth rate stands closer to 6.3%. Recent annual dividend totals underscore the steady progression: $2.84 in 2021, $2.92 in 2022, $3.00 in 2023, $3.08 in 2024, and $3.16 in 2025. Each step up has been modest but reliable. The most recent increase, declared in early 2026, raised the quarterly dividend from $0.79 to $0.82 per share, representing a roughly 3.8% year-over-year increase. This pattern of incremental, predictable growth reflects a disciplined capital allocation strategy rather than aggressive expansion of the payout.

Dividend Sustainability and Payout Ratio

Gilead's dividend appears well-supported by both earnings and free cash flow. The company's earnings-based payout ratio has recently hovered between 43% and 49%, which is well within a sustainable range for a mature biopharmaceutical company. Even more reassuring for dividend investors, the free cash flow payout ratio — which measures dividends as a percentage of free cash flow — stands at roughly 39% to 43%. This indicates that less than half of the cash generated by the business is directed toward dividend payments, leaving substantial room for reinvestment in research and development (R&D), strategic acquisitions, and share repurchases. Gilead's financial position further bolsters the dividend's safety: the company generates north of $8 billion in annual free cash flow, supported by its dominant HIV franchise and a diversified portfolio of antiviral and oncology products. While the company does carry debt on its balance sheet, the strong cash generation profile provides a comfortable cushion. Investors should note that Gilead's earnings can be lumpy due to one-time charges tied to acquisitions and R&D investments, which can temporarily inflate the payout ratio on a GAAP (Generally Accepted Accounting Principles) basis, but on a normalized earnings basis the dividend remains well-covered.

Dividend Compared to Industry Peers

Within the biopharmaceutical and drug manufacturing sector, Gilead's dividend profile stands out favorably. The healthcare sector average dividend yield is approximately 1.66%, and the drug manufacturers industry median sits near 1.85%. At roughly 2.5%, GILD offers a yield that is comfortably above those benchmarks. When compared to direct large-cap peers, Gilead's yield is competitive: AMGN yields about 2.8%, ABBV yields roughly 2.7%, and BMY provides a higher yield but with a substantially higher payout ratio. Meanwhile, several prominent biotech names — including VRTX, REGN, and BIIB — pay no dividend or only a token amount. This positions Gilead in a distinctive sweet spot: it offers a meaningful and growing income stream without the elevated payout ratios or financial strain sometimes associated with higher-yielding pharmaceutical names. For investors seeking a balance of yield, growth, and financial discipline within the healthcare sector, Gilead's dividend profile is among the more compelling.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that enables traders and investors to efficiently filter the market using a broad range of criteria, including technical patterns, fundamental metrics, volatility levels, and AI-driven trading signals. Users can scan thousands of stocks and ETFs by applying customizable filters such as industry classification, market capitalization, technical indicators, price pattern recognition, and performance statistics. The screener is particularly valuable for income-focused investors who want to identify dividend-paying stocks, evaluate yield trends, and uncover opportunities that match their investment strategy. By automating what would otherwise be a time-consuming manual research process, the AI Screener helps investors stay ahead of market movements and spot high-conviction ideas more quickly. Explore the AI Screener to begin filtering the market with precision and efficiency.

Is This Stock Attractive for Dividend Investors?

Gilead Sciences may appeal most to dividend growth investors and income-oriented investors seeking a reliable, above-average yield from a financially stable large-cap healthcare company. With an 11-year track record of consecutive annual dividend increases, a payout ratio that leaves ample room for future growth, and a yield that exceeds both the sector average and the broader market, GILD offers a balanced dividend profile. Conservative investors who prioritize capital preservation and steady income may find the combination of strong free cash flow generation and a disciplined payout policy reassuring. However, investors looking for rapid dividend growth or very high current yields may find Gilead's single-digit annual increases relatively modest. The company's exposure to patent cliffs and the inherent uncertainty of drug development also means that the dividend, while currently well-covered, is not immune to industry-specific risks. Overall, Gilead is best suited for long-term, patient investors who value consistency, financial strength, and a growing income stream within the healthcare sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations